A Case of Limb-Threatening Hematoma in a Patient Taking Citalopram and Apixaban Concurrently

Apixaban, a direct oral anticoagulant, has been demonstrated to increase the risk of bleeding in individuals with atrial fibrillation when used concurrently with citalopram [selective serotonin reuptake inhibitor (SSRI)]. This was proposed as a result of their synergistic anticoagulant effects. We d...

Descripción completa

Detalles Bibliográficos
Autores principales: Datta, Sorabh, Mahal, Karan, Mahal, Shanan, Driskill, Angela K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687801/
https://www.ncbi.nlm.nih.gov/pubmed/34950549
http://dx.doi.org/10.7759/cureus.19771
Descripción
Sumario:Apixaban, a direct oral anticoagulant, has been demonstrated to increase the risk of bleeding in individuals with atrial fibrillation when used concurrently with citalopram [selective serotonin reuptake inhibitor (SSRI)]. This was proposed as a result of their synergistic anticoagulant effects. We discuss a rare case in which a limb-threatening hematoma was noticed in an 85-year-old female patient who was just begun on citalopram and was on apixaban. There are few published case studies demonstrating a link between these two kinds of drugs, and our case study aims to inform our audience about the possible negative effects of concurrent usage of these two medications.

Ejemplares similares